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How the cellular immune response copes with diverse antigenic competition is poorly un-
derstood. Responses of virus-specific cytotoxic T lymphocytes (CTL) were examined longi-
tudinally in an individual coinfected with human immunodeficiency virus type 1 (HIV-1),
Epstein-Barr virus (EBV), and cytomegalovirus (CMV). CTL responses to all 3 viruses were
quantified by limiting dilution analysis and staining with HLA-A*0201 tetrameric complexes
folded with HIV-1, EBV, and CMV peptides. A predominance of CMV-pp65–specific CTL
was found, with a much lower frequency of CTL to HIV-1 Gag and Pol and to EBV-BMLF1
and LMP2. The high frequency of CMV-specific CTL, compared with HIV-1– and EBV-
specific CTL, was confirmed in an additional 16 HLA-A*0201–positive virus–coinfected sub-
jects. Therefore, the human immune system can mount CTL responses to multiple viral an-
tigens simultaneously, albeit with different strengths.
Prior infection with Epstein-Barr virus (EBV) and cytomeg-
alovirus (CMV) is common in individuals infected with human
immunodeficiency virus type 1 (HIV-1), and both infections are
associated with the development of a number of illnesses. EBV
is thought to cause oral hairy leukoplakia [1], interstitial pneu-
monitis [1], central nervous system (CNS) lymphoma [1, 2], and
leiomyosarcomas infection in AIDS patients [3]. CMV infection
may cause retinitis, hepatitis, and CNS disorders [4, 5]. Coin-
fection by either EBV or CMV can affect HIV-1 virus load by
several mechanisms, including transactivation of HIV-1 long
terminal repeat [6, 7] and increased rate of progression to AIDS
[8].
Cytotoxic T lymphocytes (CTL) are important in the control
of viral infections. A strong CTL response has been implicated
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in protection against HIV-1 infection in humans [9–14] and
simian immunodeficiency virus (SIV) infection in macaques
[15–18]. An inverse correlation between virus load and HIV-
1–specific CTL precursor (CTLp) frequencies in subjects with
HIV-1 infection [10] and between CTL activity and provirus
load in those with HIV-2 infection [19] has been observed. A
selective reduction of HIV-1–specific CTLp frequency occurs
in the advanced stages of HIV-1 infection [20, 21]. More re-
cently, an inverse correlation was observed between HIV-1
RNA load and the number of effector CTL cells (CTLe cells)
stained with HLA-A*0201 HIV-1 Gag and Pol tetramers [12].
Tetramer technology not only allows direct visualization of
CTL effector cells by means of flow cytometry, but also can be
used to quantify CTL without use of in vitro culture, which is
necessary for limiting dilution assay (LDA). The existence of
viral escape mutants also supports the concept of CTL control
of viral replication [9, 22, 23]. In addition, CTL activity has
been associated with protection against other human viral in-
fections, including EBV [24] and CMV [25–27] infection.
CD81 CTL recognize foreign antigens in the context of major
histocompatibility complex (MHC) class I molecules expressed
on the surface of antigen presenting cells (APCs). The amount
of antigen expressed on the surface of APCs may determine
the functional status of the T cells [28, 29] and also the gen-
eration and maintenance of CTL [30–33]. Coinfection by het-
erologous viruses in lymphocytic choriomeningitis virus
(LCMV)–infected mice resulted in a constant reduction of
LCMV-specific CTLp [34]. This phenomenon is thought to be
important in the maintenance of lymphoid system homeostasis.
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In humans, the effects of viral coinfections on HIV-1–specific
CTL are not well documented. A few studies have measured
EBV-specific CTL responses in HIV-1–infected individuals [20,
35, 36], but none have also examined CMV-specific CTL re-
sponses. As simultaneous infection with several viruses may
present antigenic competition and reduce the HIV-1–specific
response, it is important to ascertain whether EBV and CMV
coinfections will influence the development of HIV-1–specific
CTL.
We identified a patient (SC-15) who had been coinfected with
HIV-1, EBV, and CMV and examined his clinical, virological,
and immunological parameters over 20 months. In addition,
we performed a longitudinal quantitative analysis of viral-spe-
cific CTL responses over 20 months by use of 2 different meth-
ods: (1) LDA for HIV-1–, EBV-, and CMV-specific CTLp and
(2) tetramer staining for HLA-A*0201–restricted HIV-1–,
EBV-, and CMV-specific CTLe. Dominant HLA-A*0201–
restricted CMV-specific CTLe were found in patient SC-15
throughout the 20-month follow-up period, and a dominance
of CMV-specific CTLe was further observed in an additional
16 patients at different stages of HIV-1 infection.
Materials and Methods
Study subjects. Subject SC-15 is a 30-year-old homosexual
man. He first presented to his primary care physician with signs
of primary viral infection and was determined to be HIV-1 positive
by serologic analysis and Western blot testing in May 1996. A
persistent lymphadenopathy invoked further laboratory examina-
tions. CMV serologic analysis was performed by use of the Sorin
Capture assay (CSL, Melbourne, Australia), yielding results con-
sistent with either primary infection or reactivation of a recent
infection. EBV serologic analysis was done by use of a component
system, with antigen and control from Gull (Salt Lake City) and
detection reagents from Silenus Laboratories (Melbourne) or Sigma
(St. Louis). The HLA type of SC-15 is HLA-A2, A14, B44, DR07,
DR12. The patient began antiretroviral therapy with stavudine,
lamivudine, and saquinavir in June 1996 and continued on this
therapy throughout the 2-year study period. The additional 16
patients included in this study were HLA-A*0201 positive and were
chosen from various study cohorts established at the Aaron Dia-
mond AIDS Research Center, New York. EBV and CMV infection
were confirmed by serologic testing.
Measurement of HIV-1 virus load. Viral RNA copy numbers
in plasma were determined either by reverse-transcriptase poly-
merase chain reaction on samples by use of the Amplicor HIV-1
monitor kit (Roche Molecular Systems, Branchburg, NJ), which
has a detection limit of 400 copies/mL [37], or by the bDNA signal-
amplification assay (Chiron, San Francisco), which has detection
limit of 50 and 500 Eq/mL.
Recombinant vaccinia viruses. Recombinant vaccinia express-
ing HIV-1 antigens were vAbT 299 (IIIBenv-gp160), vAbT 141
(IIIBgag-p55), vAbT 204 (IIIBpol), and rVV-IIIBnef, obtained
from Dr. G. Mazzara (Therion Biologics, Boston) [11]. The EBV
antigens expressed by recombinant vaccinia were EBNA3a,
EBNA3b, EBNA3c, LMP2, BRLF1, and BMLF1, and the CMV
antigens expressed by recombinant vaccinia were pp65, pp150, gB,
and IE1. The control vaccinia used for all the experiments was a
tk-virus in which the thymidine kinase gene was inactivated by
insertion of a vector (pSC11) into the WR strain.
Establishing primary fibroblast cell lines. Primary fibroblast cell
lines were established according to a procedure described elsewhere
[27, 38]. Briefly, skin biopsy samples (4–5 mm2, 0.5–1 mm depth)
were taken from the inside of the upper arm under 1% lignocaine
local anesthesia. The skin biopsy samples were processed further
into smaller sections and cultured in petri dishes under a glass cover
slip in MEM enriched with fetal calf serum. Outgrowth of fibro-
blasts occurred within 7–10 days, and a fibroblast line was sub-
sequently established.
LDA. Three sets of LDA plates were set up simultaneously
by use of cryopreserved peripheral blood mononuclear cells
(PBMC), each with 8 input cell dilution, with a range of 0–32,000
cells/well. In addition, gamma-irradiated allogeneic42.5 3 10
PBMC and 0.1 mg/mL anti-CD3 (clone 12F6) were added to each
well. The cultures were kept growing for 14 days with twice a week
medium change, using standard RPMI-1640 supplemented with
100 U/mL interleukin (IL)–2 and 15% fetal calf serum. A standard
4-h 51Cr release assay was performed on days 13 and 14: each LDA
plate was split 6 ways and assayed against autologous primary
fibroblasts that had been infected with either control vaccinia or
recombinant vaccinia expressing HIV-1, EBV, or CMV antigens.
A well was regarded as positive for specific CTL activity only when
the percentage of specific lysis exceeded 10% and was 10% more
than that of the corresponding control target cells. The antigen-
specific CTLp frequencies, after subtracting the background lysis
to target cells infected with control recombinant vaccinia, were
determined by use of the maximum likelihood method by means
of a Microsoft Excel spreadsheet (kindly provided by Dr. S. Ka-
lams, Massachusetts General Hospital, Boston), and the results
were expressed as the number of CTLp per 106 input CD81 PBMC.
MHC class I tetramer staining. MHC class I tetramers were
synthesized according to methods described elsewhere [12 39] and
were folded with each of the following peptides: HIV-1–Gag (77-
85: SLYNTVATL); Pol (476-484: ILKEPVHGV); EBV-LMP2
(426-434: CLGGLLTMV); BMLF1 (280-288: GLCTLVAML); and
CMV-pp65 (495-503:NLVPMVATV). Cryopreserved PBMC from
different time points were thawed and were stained with phyco-
erythrin-conjugated tetramers in conjunction with CD38 fluores-
cein isothiocyanate and CD8Tricolour (Caltag, Burlingame, CA).
The triple-color stained PBMC samples were analyzed by use of a
flow cytometer (Calibur; Becton Dickinson, San Jose, CA), and
results were presented as percentage of CD381 and tetramer-pos-
itive cells in the CD81 cell population. The statistical differences
between all groups of patients were analyzed by use of a standard
single factor analysis of variance (ANOVA) test and a nonpara-
metric Kruskal-Wallis test [40].
Results
Coinfection with HIV-1, EBV, and CMV in subject SC-15.
Subject SC-15 was negative for HIV-1, EBV, and CMV by
serology in February 1996. He first presented to his primary
care physician with signs of primary viral infection in May 1996,
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Figure 1. Clinical information over time. A, Plasma human im-
munodeficiency virus (HIV) viral load measurement was performed by
use of a commercial reverse transcriptase–polymerase chain reaction
method; B, CD41 and CD81 cell counts were determined by use of a
routine clinical method, as described in Materials and Methods.
Table 1. Clinical diagnosis of coinfections in subject SC-15.
Virus Laboratory tests (result) Date
HIV Negative 2/1/96
Ab (1), Ag (1), WB (1) 5/22/96
Ab (1), Ag (1), WB (1) 5/29/96
Viral culture (1) 6/25/96
EBV Negative 2/1/96
IgM (1), IgG (?) 6/21/96
IgM (1), IgG (?) 6/25/96
IgM (2), IgG (1) 7/8/96
CMV Negative 2/1/96
IgM (?), IgG (1) 6/21/96
IgM (1), IgG (1) 6/25/96
IgM (2), IgG (1) 7/8/96
NOTE. CMV, cytomegalovirus; EBV, Epstein-Barr virus; HIV, human im-
munodeficiency virus; 1, test positive; 2, test negative; ?, test equivocal.
and repeated serology and Western blot testing yielded a di-
agnosis of HIV-1 positivity. A persistent lymphadenopathy in-
voked further laboratory examinations, which found him to be
EBV VCA IgG equivocal and IgM positive by one test on 21
June and another test on 25 June, and subsequently, on 8 July
1996, he was found to be IgG positive and IgM negative. His
CMV serology followed a similar course, with IgG positive and
IgM equivocal by one test on 21 June and both IgG and IgM
positive on 25 June. This CMV serological profile is suggestive,
but not affirmative, of a primary infection; nonetheless, it is
also consistent with reactivation of a recent infection. Subse-
quently he was IgG positive and IgM negative on 8 July 1996
(table 1). The patient was treated with antiretroviral therapy
(stavudine, lamivudine, and saquinavir) on 25 June 1996.
Combination antiretroviral therapy controlled HIV-1 replica-
tion and resulted in rapid resolution of CD81 lymphocytosis.
The virological and immunological changes in patient SC-15
were similar to those in others who have been treated success-
fully with combination therapy [41]. Within 3 weeks of the
initiation of antiretroviral therapy with stavudine, lamivudine,
and saquinavir, his plasma HIV-1 RNA levels dropped by 12
logs from 140,000 copies to !770 copies/mL. Additional therapy
further reduced the HIV-1 RNA load to !400 copies (the level
of detection) within 3 months (figure 1A). Over the same period,
his CD81 cell count declined from 4080 to 920/mL, then re-
mained at a stable level for ∼12 months; meanwhile, although
the absolute CD41 cell count fluctuated, his CD4 : CD8 ratio
was approaching 1 : 1 (figure 1B). To determine the impact of
antiretroviral therapy on the generation of CTL and the pos-
sible interference in the generation of HIV-1–specific CTL by
other viral coinfections, we quantified his CTLp frequency spe-
cific for HIV-1, EBV, and CMV.
Broadly reactive CTL were generated during primary HIV-1
infection. To determine the impact of EBV and CMV coin-
fections on the normal development of the HIV-1–specific CTL
response during primary infection, we did a longitudinal quan-
titative study of the HIV-1–specific CTLp, using the LDA.
Moderate levels of CTL (CTLp from per 106 CD8138 5 7
PBMC) specific for HIV-1 Env, Gag, and Pol antigens were
detected on the day of initiation of combination antiretroviral
therapy. The number of HIV-1–specific CTL declined rapidly
over the first few weeks, concomitant with the precipitous drop
in virus load during the same period. However, the magnitude
of these CTLp frequencies rebounded back to 50% of the start-
ing levels soon afterward and remained at relatively stable levels
for the next 20 months (figure 2 A, B, C). The time of rebound
overlaps with the time of a transient virus load increase at week
4 to 5, so a boosting of the preexisting memory CTL might
have occurred. Nef-specific CTLp were also detected at lower
levels (figure 2D). Thus, simultaneous coinfection by 2 other
herpesviruses did not have significant interference with the nor-
mal course of development of the HIV-1–specific CTL in this
patient.
Sequential induction of the EBV-specific CTLp to various viral
antigens. In contrast to the broadly reactive HIV-1–specific
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Figure 2. Detection of human immunodeficiency virus type 1 (HIV-1)–specific cytotoxic T lymphocytes (CTL). CTL precursor (CTLp) frequency
was determined by use of limiting dilution assay (LDA). Effector cells were peripheral blood mononuclear cells (PBMC) cultured under LDA
conditions; target cells were autologous primary fibroblasts that had been infected with either control vaccinia or recombinant vaccinia expressing
HIV-1 antigens. A, IIIBenv-gp160; B, IIIBgag-p55; C, IIIBpol; and D, IIIBnef. All CTLp frequencies were presented as per 106 CD81 T cells.
CTL generated during the first 2–3 weeks, the EBV-specific
CTL activity that developed was focused on the early viral
antigen, primarily to BRLF1 (figure 3A). Over time, however,
their dominance gave way to CTL reactive to other EBV an-
tigens, LMP2 and EBNA3b/3c (figure 3B); in addition,
EBNA3b seems to contain the dominant CTL epitopes among
these antigens (figure 3B).
CTL to IE1 epitopes were detected during coinfection.
CMV-specific CTL activity during coinfection with EBV and
HIV-1 has not been described elsewhere; therefore, this patient
provided a unique opportunity for examining the kinetics of
both the induction of CMV-specific CTL and the impact of
antiretroviral therapy on the development of CMV-specific
CTL during coinfection. As shown in figure 4, CTL specific
for the IE1 antigen were generated during the first week of
therapy and remained at appreciable levels throughout the 20-
month study period. In contrast, there was a delay of 1–2 weeks
for CTL to other structural components, namely, gB, pp65,
and pp150, to reach peak levels. In addition, the absolute num-
bers of CTLp to these structural proteins were less than for
IE1.
The most abundant CTLe during the triple coinfections were
CMV specific. Although the LDA has been widely used for
quantifying memory CTL, a new technology, staining antigen-
specific CD81 T cells with MHC tetramers, has proved to be
a powerful alternative for quantifying CTLe [12, 39]. We there-
fore decided to examine the correlation between the number of
CTL determined by these 2 methods. PBMC samples were
stained with 5 HLA-A*0201 tetramers folded with different
immunodominant peptides: (1) HIV-1-Gag (77-85: SLYNT-
VATL); (2) HIV-1-Pol (476-484: ILKEPVHGV); (3) EBV im-
mediate early antigen BMLF1 (280-288: GLCTLVAML); (4)
EBV latent antigen LMP2 (426-434: CLGGLLTMV); and (5)
CMV structure protein antigen pp65 (495-503: NLVPMVATV).
There was a dominance of HLA-A*0201–restricted CMV-spe-
cific CTLe, as high as 4.4 % of total CD81 cells, whereas the
frequencies of CTLe specific for HIV-1 and EBV were much
lower (figure 5). To test whether CTLp recognized the same
peptides used in the CTLe tetramer assay, LDAs were set up
by using conventional polyclonal stimulation with anti-CD3
and then assayed against peptide-pulsed target cells. The results
demonstrated a similar CTLp frequency to all the peptide an-
tigens (data not shown).
Because the tetramer staining for the HLA-A*0201 CMV-
specific CTLe was the most prominent among the 5 tetramers
used, we further followed the quantity of these cells with the
CMV tetramer. As shown in figure 6, there was a rapid decline
in the number of tetramer-positive cells during the first few
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Figure 3. Detection of Epstein-Barr virus (EBV)–specific cytotoxic T lymphocytes (CTL). The following EBV antigens were included: A,
BRLF1; B, BMLF1; C, LMP2; D, EBNA3a; E, EBNA3b; and F, EBNA3c. CTLp, CTL precursor; PBMC, peripheral blood mononuclear cells.
days of antiretroviral therapy. Their number was then stabilized
at ∼25%–50 % of the peak level for the next 20 months.
Dominance of CMV-specific CTLe in HIV-1, EBV, and CMV
coinfections. Having shown the dominance of CMV-specific
CTLe in 1 patient, we hypothesized that this might be a more
generalized phenomenon. Because prior EBV and CMV infec-
tions are common in the general population [42–44], the ma-
jority of HIV-1–infected individuals are likely to harbor EBV
and CMV viruses. We therefore selected 16 HIV-1–infected
HLA-A*0201 individuals for a cross-sectional study of CTLe
frequency using tetramers to HIV-1, EBV, and CMV. The pa-
tients selected were a mixture of acute seroconverters and chron-
ically infected individuals. Some of the samples were obtained
before the initiation of antiretroviral therapy, others after (table
2). Those patients with CTLe for all 3 viruses are presented in
figure 7. Pre- and posttreatment data were analyzed by use of
the same statistical methods. A standard single factor ANOVA
showed a significant difference between the pretreatment data
on the mean percentage of CD81 cells stained with tetramers
for A*0201/Gag, A*0201/Pol, A*0201/BMLF1, A*0201/
LMP2, and A*0201/CMV ( ). Pairwise multiple com-P ! .01
parison (Dunnett’s method) of the A*0201/CMV group mean
and all other means showed that the A*0201/CMV mean is
significantly different from the other means, at . A non-P ! .001
parametric Kruskal-Wallis test of the 5 groups was significant
at . For the posttreatment data on the mean percentageP ! .05
of CD81 cells stained with tetramers for A*0201/Gag, A*0201/
Pol, A*0201/BMLF1, A*0201/LMP2, and A*0201/CMV, a
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Figure 4. Detection of cytomegalovirus (CMV)–specific cytotoxic T lymphocytes (CTL). The following CMV antigens were included: A, IE1;
B, pp65; C, pp150; and D, gB. CTLp, CTL precursor; PBMC, peripheral blood mononuclear cells.
Figure 5. Cytomegalovirus (CMV)–specific effector cytotoxic T lymphocytes (CTLe) were the dominant effector cells during coinfections in
patient SC-15. Peripheral blood mononuclear cells (PBMC) during the first week of therapy were stained with the following: A, human immu-
nodeficiency virus type 1 (HIV-1)–Gag; B, HIV-1–Pol; C, Epstein-Barr virus (EBV)–BMLF1; D, EBV-LMP2; and E, CMV-pp65 tetramers, as
described in Materials and Methods. Data presented are percentage of tetramer-positive CD81 T cells. FITC, fluorescein isothiocyanate.
standard single factor ANOVA revealed a significant difference
at . Pairwise multiple comparison showed that theP ! .025
A*0201/CMV group mean was significantly different from the
other means at . A nonparametric test could not beP ! .001
performed, because of the low number of data points per group.
Discussion
Although EBV and CMV coinfections are common in in-
dividuals with HIV-1 infection, it is extremely rare to see pa-
tients with primary HIV-1, EBV, and CMV coinfections. In
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Figure 6. Cytomegalovirus (CMV)–specific effector cytotoxic T
lymphocytes (CTLe) persisted at high levels for 20 months in patient
SC-15. Sequential samples were stained with human immunodeficiency
virus type 1 (HIV-1)–Gag (L), HIV-1–Pol (M), Epstein-Barr virus
(EBV)–BMLF1 (n), EBV-LMP2 tetramers (V), and CMV-pp65 (l),
as described in figure 5 legend. Results presented are percentage of
tetramer-positive CD81 T cells.
Table 2. Clinical characteristics of patients included in the cross-
sectional tetramer staining.
Patient
ID no.
Time of blood sample Findings
Date
Stage of
infection
Antiretroviral
therapya
CD41
cells/mL
CD81
cells/mL
Virus load,
copies/mL
2004 1/21/97 Acute Before 47 671 633,230
2003 12/5/96 Acute Before 596 917 563,760
913 9/4/97 Acute Before 697 1045 22,420
911 3/13/97 Acute Before 685 1134 21,800
1013 9/24/96 Chronic Before 124 1135 786,372
1010 9/11/96 Chronic Before 284 320 248,433
33 2/9/96 Chronic Before 557 3101 242,700
1002 9/3/96 Chronic Before 537 1096 76,916
1004 9/3/96 Chronic Before 402 660 27,077
1009 9/4/96 Chronic Before 665 927 22,288
1306 12/2/97 Acute After 720 1241 99
1309 1/16/98 Acute After 659 288 99
1302 10/15/97 Acute After 627 627 99
912 12/11/97 Acute After 579 434 99
2004 1/14/98 Acute After 308 1322 61
3 2/21/97 Acute After 426 352 50
a Time of sample relative to the start of antiretroviral therapy.
mice it was demonstrated that immunodominance of 1 CTL
epitope over the others was established during primary lym-
phocytic choriomeningitis virus (LCMV) infection [45]. How-
ever, subsequent infection by heterologous viruses perturbs the
existing memory CTL response to the initial inoculating LCMV
[34]. This case offered a unique opportunity to examine CTL
responses to multiple viral coinfections. We observed that CTL
responses to HIV-1, EBV, and CMV developed simultaneously.
Therefore, the host immune system has the potential of coping
with a diversity of viral infections simultaneously during pri-
mary infection. The kinetics of these CTL responses, however,
differed from each other. In addition, by studying the preva-
lence of CTLe to various viral antigens in an additional 16
HLA-A*0201–individuals with HIV-1, EBV, and CMV coin-
fections, we demonstrated that CMV-pp65–specific CTL were
the most prevalent effector cells among all effector cell
populations.
The CTL response to multiple HIV-1 antigens, including Env,
Gag, Pol, and Nef, developed early in subject SC-15. These
observations are in agreement with published data [9, 11]. Our
study, however, further illustrated the kinetics of HIV-1–specific
CTL during antiretroviral therapy. After the initial appearance
of a broadly reactive CTL response, the level of these CTLp
declined rapidly over the first few weeks after the onset of
combination therapy, concomitant with the precipitous drop of
virus load during the same period. The magnitude of these
CTLp rebounded to the starting levels soon afterward and re-
mained relative stable for the next 18 months. The initiation
of the CTLp rebound was associated closely with a transient
virus load increase, suggesting that this may have boosted the
preexisting memory CTL. Another possibility is that coinfec-
tion by EBV and CMV leads to more T-cell activation with
increased production of cytokines, thereby nonspecifically ac-
tivating the HIV-1–specific memory CTL. The persistence of
these CTL may indicate there are still low levels of viral rep-
lication in either the blood or the lymph nodes.
In patient SC-15, EBV and CMV coinfections did not have
adverse effects on the normal development and maintenance
of HIV-1–specific CTL during primary infection. In contrast
to the broadly reactive HIV-1–specific CTL during the first 2–3
weeks, the EBV-specific CTL activity was focused on the early
viral antigens, namely, BRLF1 and BMLF1. Over time, how-
ever, their dominance gave way to CTL reactive to the late
EBV antigens LMP2 and EBNA3b/3c, of which EBNA3b
seemed to contain the most dominant CTL epitopes among
late antigens. Such a highly prevalent CTL response to EBV
early antigens during primary EBV infection has also been ob-
served by others [42, 46]. The rapid expansion and contraction
of the number of CTLp is consistent with an EBV-driven CTL
evolution process [42, 47]. Furthermore, because the pattern of
EBV-specific CTLp fluctuation was independent of changes in
the HIV-1 virus load, the antiretroviral therapy did not appear
to have a direct impact on the normal course of development
of the EBV-specific CTL activity.
The development of CMV-specific CTL response was similar
to that of EBV; that is, the initial CTL response was mostly
specific for early antigens, followed by responses to antigens
encoded by the later structural genes. Memory CTL specific
for the IE1 antigen were detected during the first week of ther-
apy and remained at an appreciable level throughout the 20-
month study period. In contrast, there was a delay of 1–2 weeks
for CTL to other structural components (gB, pp65, and pp150)
to reach peak levels. Although CTL responses to both IE1 and
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Figure 7. Cross-sectional study revealed the dominance of cytomegalovirus (CMV)–specific effector cytotoxic T lymphocytes (CTLe) in an
additional 16 patients. Peripheral blood mononuclear cells (PBMC) from a single time point of each of the patients in table 1 were stained with
human immunodeficiency virus type 1 (HIV-1)–Gag, HIV-1–Pol, Epstein-Barr virus (EBV)–BMLF1, EBV-LMP2, and CMV-pp65 tetramers.
Results presented are percentage of tetramer-positive CD81 T cells. “Pre” and “Post” indicate pre- and posttreatment data for the designated
patients.
pp65 CMV antigens have been described in healthy, asymp-
tomatic individuals [5, 48], CTL activity during primary CMV
infection has not been described previously. It is interesting to
note that there were more CTL to pp65 than to IE1 antigen
during chronic CMV infection [49]. This discrepancy in the
dominant CTL response may be a genuine reflection of the
difference in acute versus chronic CMV infection. Indeed, the
absolute frequencies of IE1-specific CTL (1–30/106 CD81
PBMC) we observed during acute infection are in the same
range as reported by others [27, 38]. The pp65-specific CTLp
frequency detected was lower than reported previously [49] and
much lower than we would have expected based on staining
with the CMV tetramer. This lower than expected pp65-specific
CTLp might be the result of the stimulation procedure used in
generating memory CTL. We deliberately chose to use a poly-
clonal anti-CD3 monoclonal antibody to expand all the T cells,
because we wanted to quantify all the CTL to all 3 viruses
simultaneously. In contrast, others have used either CMV-in-
fected fibroblasts or peptide-labeled BLCL as stimulator cells
for the generation of CMV-specific CTL [27, 38, 49]. If tetra-
mers specific for the IE1 epitopes were available, it would be
useful to follow CMV-specific CTL responses with both IE1-
and pp65-specific tetramers to see what the magnitude of IE1-
specific CTLe is in comparison with pp65-specific CTLe. Fur-
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thermore, because the kinetics of the CMV tetramer staining
cells is similar to that of the total CD81 cell count (figure 1B)
but differs from the kinetics of HIV-1–specific CTLp, this result
indicates an HIV-1 antigen–independent evolution of CMV-
specific CTLe.
One striking finding is the dominance of CMV-specific CTLe
in those who have contracted HIV-1, EBV, and CMV triple
coinfections. Although memory CTL to all these viruses exist
and their frequencies are similar, each has a different rate of
expansion into effector cells. One possible explanation is that
different viral antigens are processed and presented with dif-
ferent efficiency. Among all permissive cells, the principal target
cells for HIV-1 are CD41 T cells and for EBV are epithelial
and B cells [48, 50], whereas for CMV, the target cells are
monocytes and macrophages [51, 52]. Whereas B cells and ep-
ithelium cells can present antigen, only the macrophage is the
professional antigen-presenting cell. Thus, the CMV antigens
are likely to be presented to CTL preferentially, given that the
other conditions are equal. Furthermore, some of the CMV
proteins are associated with MHC class I down regulation [53],
which could result in decreased presentation of other viral an-
tigens, therefore resulting in an inhibition of the processing and
presentation of other antigens. Because CMV has the advan-
tage of gaining entry to professional antigen presenting cells
and a subsequent advantage in antigen presentation, it is not
surprising that CTL to CMV are still generated in vivo.
It is also possible that the observed differences in CTLe levels
were a reflection of the variable T-helper activities to different
viruses. Defects in the HIV-1–specific T-helper cells during pri-
mary infection have been well documented; therefore, stronger
T-helper responses may have been induced to EBV and CMV
than to HIV-1. It is also known that CMV pp65 contains a
number of T-helper epitopes [25, 49]. However, whether the
pp65-specific T-helper activity was stronger than that of EBV-
specific T-helper activity is yet to be determined.
Although the LDA has been the standard method widely
used for quantifying the precursors of memory CTL (CTLp),
staining antigen-specific CD81 T cells with MHC tetramers has
proved to be a powerful alternative for quantifying CTLe. The
number of CTL measured by LDA is very much lower than
that measured by tetramer, as is seen in our results. By using
these tetramers (including HIV-1-Gag, HIV-1-Pol, EBV-
BMLF1, EBV-LMP2, and CMV-pp65), we found that the most
abundant CTLe during the triple coinfections were CMV spe-
cific, consisting of ∼5% of total CD8 cells, whereas the other
effector cells were at much lower levels. Because the tetramers
define viral CTL recognizing a few dominant epitopes restricted
through HLA-A*0201, it is possible that CTL in subject SC-
15 recognize HIV-1 and EBV antigens that were not included
in the study, or recognize similar epitopes through HLA alleles
other than A*0201. HLA-A*0201 may not be a major presen-
tation allele for EBV. It has been demonstrated, in a population
where HLA-A11 is highly prevalent, that the endogenous EBV
strains in those populations are mutated at A11 anchor residue
[24]. HLA-A*0201 reactivity may have followed a similar pat-
tern in the patients we have studied. Our results indicate that
CMV accounts for the majority of HLA-A*0201–restricted
CTL.
It is interesting to note that the variation of CMV-specific
CTLe followed kinetics similar to those of the absolute CD81
cell count. Specifically, there was a high level of CMV-specific
CTLe initially, which rapidly fell during the first few days of
the antiretroviral therapy, then stabilized at ∼10%–15% of the
peak level for the next 6 months. This could be due to a re-
duction of CMV virus load over the same period, reflecting an
antigen-driven CTL evolution, or to a nonspecific event asso-
ciated with the general reduction of immune activation, as a
consequence of the control of HIV-1 replication by antiretro-
viral therapy.
In this study, we used 2 different methods to quantify HIV-
1–, EBV-, and CMV-specific CTL in a patient with triple coin-
fections. Each method provided complementary information
on the dynamics and kinetics of CTL development in response
to multiple external pathogens. LDA and the tetramer staining
method may not be measuring the same population of cells.
Whereas MHC tetramers are more useful in quantifying epi-
tope-specific CTL in subjects with known HLA types, the LDA
method is useful to examine the breadth of CTL to a large
number of antigens and also to detect memory cells with pro-
liferation potential. For a thorough investigation of host im-
mune potential, both methods are needed.
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